Growth standards of patients with Noonan and Noonan-like syndromes with mutations in the RAS/MAPK pathway

American Journal of Medical Genetics, Part A

Volumn 158 A, Issue 11, 2012, Pages 2700-2706

  Malaquias, Alexsandra C ^a   Brasil, Amanda S ^a   Pereira, Alexandre C ^a   Arnhold, Ivo J P ^a   Mendonca, Berenice B ^a   Bertola, Debora R ^a   Jorge, Alexander A L ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Body mass index; Growth charts; Noonan syndrome; Noonan like syndrome; Short stature

Indexed keywords

B RAF KINASE; K RAS PROTEIN; PROTEIN TYROSINE PHOSPHATASE SHP 2; SOS PROTEIN;

ADOLESCENT; ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BIRTH LENGTH; BIRTH WEIGHT; BODY HEIGHT; BODY MASS; BODY WEIGHT; BRAF GENE; CHILD; FEMALE; GENOTYPE; GESTATIONAL AGE; GROWTH CURVE; HUMAN; INFANT; KRAS GENE; MAJOR CLINICAL STUDY; MALE; NEWBORN; NOONAN LIKE SYNDROME; NOONAN SYNDROME; POSTNATAL GROWTH; PREMATURITY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN TYROSINE PHOSPHATASE NONRECEPTOR TYPE 11 GENE; RAF1 GENE; RAS MAPK SIGNALING PATHWAY; REFERENCE VALUE; SCHOOL CHILD; SHOC2 GENE; SIGNAL TRANSDUCTION; SOS1 GENE;

FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; GRANULOMA, GIANT CELL; GROWTH CHARTS; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MUTATION; NOONAN SYNDROME; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 84867843251     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.35519     Document Type: Article

References (33)

1. Allanson JE. 1987. Noonan syndrome. J Med Genet 24: 9-13.
2. Baldassarre G, Mussa A, Dotta A, Banaudi E, Forzano S, Marinosci A, Rossi C, Tartaglia M, Silengo M, Ferrero GB. 2011. Prenatal features of Noonan syndrome: Prevalence and prognostic value. Prenat Diagn 31: 949-954.
3. Bentires-Alj M, Kontaridis MI, Neel BG. 2006. Stops along the RAS pathway in human genetic disease. Nat Med 12: 283-285.
4. Brasil AS, Malaquias AC, Wanderley LT, Kim CA, Krieger JE, Jorge AA, Pereira AC, Bertola DR. 2010a. Co-occurring PTPN11 and SOS1 gene mutations in Noonan syndrome: Does this predict a more severe phenotype? Arq Bras Endocrinol Metabol 54: 717-722.
5. Brasil AS, Pereira AC, Wanderley LT, Kim CA, Malaquias AC, Jorge AA, Krieger JE, Bertola DR. 2010b. PTPN11 and KRAS gene analysis in patients with Noonan and Noonan-like syndromes. Genet Test Mol Biomarkers 14: 425-432.
6. Cole TJ, Green PJ. 1992. Smoothing reference centile curves: The LMS method and penalized likelihood. Stat Med 11: 1305-1319.
7. Cordeddu V, Di Schiavi E, Pennacchio LA, Ma'ayan A, Sarkozy A, Fodale V, Cecchetti S, Cardinale A, Martin J, Schackwitz W, Lipzen A, Zampino G, Mazzanti L, Digilio MC, Martinelli S, Flex E, Lepri F, Bartholdi D, Kutsche K, Ferrero GB, Anichini C, Selicorni A, Rossi C, Tenconi R, Zenker M, Merlo D, Dallapiccola B, Iyengar R, Bazzicalupo P, Gelb BD, Tartaglia M. 2009. Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. Nat Genet 41: 1022-1026.
8. Ferreira LV, Souza SA, Arnhold IJ, Mendonca BB, Jorge AA. 2005. PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with Noonan syndrome. J Clin Endocrinol Metab 90: 5156-5160.
9. Ferreira LV, Souza SC, Montenegro LR, Malaquias AC, Arnhold IJ, Mendonca BB, Jorge AA. 2008. Analysis of the PTPN11 gene in idiopathic short stature children and Noonan syndrome patients. Clin Endocrinol (Oxf) 69: 426-431.
10. Horton WA, Rotter JI, Rimoin DL, Scott CI, Hall JG. 1978. Standard growth curves for achondroplasia. J Pediatr 93: 435-438.
11. Jorge AA, Malaquias AC, Arnhold IJ, Mendonca BB. 2009. Noonan syndrome and related disorders: A review of clinical features and mutations in genes of the RAS/MAPK pathway. Horm Res 71: 185-193.
12. Ko JM, Kim JM, Kim GH, Yoo HW. 2008. PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome. J Hum Genet 53: 999-1006.
13. Kobayashi T, Aoki Y, Niihori T, Cave H, Verloes A, Okamoto N, Kawame H, Fujiwara I, Takada F, Ohata T, Sakazume S, Ando T, Nakagawa N, Lapunzina P, Meneses AG, Gillessen-Kaesbach G, Wieczorek D, Kurosawa K, Mizuno S, Ohashi H, David A, Philip N, Guliyeva A, Narumi Y, Kure S, Tsuchiya S, Matsubara Y. 2010. Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: Dephosphorylation of serine 259 as the essential mechanism for mutant activation. Hum Mutat 31: 284-294.
14. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Guo SS, Wei R, Mei Z, Curtin LR, Roche AF, Johnson CL. 2000. CDC growth charts: United States. Adv Data 1-27. PMID: 11183293.
15. Mendez HM, Opitz JM. 1985. Noonan syndrome: A review. Am J Med Genet 21: 493-506.
16. Ministerio da Saude. 2010. Health Brazil 2010: Health analysis and selected evidences on impact of health surveillance actions. Brasilia: Ministerio da Saude. 372 p.
17. Pandit B, Sarkozy A, Pennacchio LA, Carta C, Oishi K, Martinelli S, Pogna EA, Schackwitz W, Ustaszewska A, Landstrom A, Bos JM, Ommen SR, Esposito G, Lepri F, Faul C, Mundel P, Lopez Siguero JP, Tenconi R, Selicorni A, Rossi C, Mazzanti L, Torrente I, Marino B, Digilio MC, Zampino G, Ackerman MJ, Dallapiccola B, Tartaglia M, Gelb BD. 2007. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 39: 1007-1012.
18. Pena SD, Di Pietro G, Fuchshuber-Moraes M, Genro JP, Hutz MH, Kehdy Fde S, Kohlrausch F, Magno LA, Montenegro RC, Moraes MO, de Moraes ME, de Moraes MR, Ojopi EB, Perini JA, Racciopi C, Ribeiro-Dos-Santos AK, Rios-Santos F, Romano-Silva MA, Sortica VA, Suarez-Kurtz G. 2011. The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected. PLoS ONE 6: e17063.
19. Ranke MB, Pfluger H, Rosendahl W, Stubbe P, Enders H, Bierich JR, Majewski F. 1983. Turner syndrome: Spontaneous growth in 150 cases and review of the literature. Eur J Pediatr 141: 81-88.
20. Ranke MB, Heidemann P, Knupfer C, Enders H, Schmaltz AA, Bierich JR. 1988. Noonan syndrome: Growth and clinical manifestations in 144 cases. Eur J Pediatr 148: 220-227.
21. Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME, Roberts AE, Robinson W, Takemoto CM, Noonan JA. 2010. Noonan syndrome: Clinical features, diagnosis, and management guidelines. Pediatrics 126: 746-759.
22. Schwartz MW, Seeley RJ. 1997. Seminars in medicine of the Beth Israel Deaconess Medical Center. Neuroendocrine responses to starvation and weight loss. N Engl J Med 336: 1802-1811.
23. Shaw AC, Kalidas K, Crosby AH, Jeffery S, Patton MA. 2007. The natural history of Noonan syndrome: A long-term follow-up study. Arch Dis Child 92: 128-132.
24. Silva DA, Pelegrini A, Petroski EL, Gaya AC. 2010. Comparison between the growth of Brazilian children and adolescents and the reference growth charts: Data from a Brazilian project. J Pediatr (RioJ) 86: 115-120.
25. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt I, Crosby AH, Ion A, Jeffery S, Kalidas K, Patton MA, Kucherlapati RS, Gelb BD. 2001. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 29: 465-468.
26. Tartaglia M, Pennacchio LA, Zhao C, Yadav KK, Fodale V, Sarkozy A, Pandit B, Oishi K, Martinelli S, Schackwitz W, Ustaszewska A, Martin J, Bristow J, Carta C, Lepri F, Neri C, Vasta I, Gibson K, Curry CJ, Siguero JP, Digilio MC, Zampino G, Dallapiccola B, Bar-Sagi D, Gelb BD. 2007. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 39: 75-79.
27. Tartaglia M, Zampino G, Gelb BD. 2010. Noonan syndrome: Clinical aspects and molecular pathogenesis. Mol Syndromol 1: 2-26.
28. Tartaglia M, Gelb BD, Zenker M. 2011. Noonan syndrome and clinically related disorders. Best Pract Res Clin Endocrinol Metab 25: 161-179.
29. Tidyman WE, Rauen KA. 2009. The RASopathies: Developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev 19: 230-236.
30. Usher R, McLean F. 1969. Intrauterine growth of live-born Caucasian infants at sea level: Standards obtained from measurements in 7 dimensions of infants born between 25 and 44 weeks of gestation. J Pediatr 74: 901-910.
31. WHO. 2006. WHO Child Growth Standards based on length/height, weight and age. Acta Paediatr Suppl 450: 76-85.
32. Witt DR, Keena BA, Hall JG, Allanson JE. 1986. Growth curves for height in Noonan syndrome. Clin Genet 30: 150-153.
33. Zenker M, Horn D, Wieczorek D, Allanson J, Pauli S, van der Burgt I, Doerr HG, Gaspar H, Hofbeck M, Gillessen-Kaesbach G, Koch A, Meinecke P, Mundlos S, Nowka A, Rauch A, Reif S, von Schnakenburg C, Seidel H, Wehner LE, Zweier C, Bauhuber S, Matejas V, Kratz CP, Thomas C, Kutsche K. 2007. SOS1 is the second most common Noonan gene but plays no major role in cardio-facio-cutaneous syndrome. J Med Genet 44: 651-656.